Immune globulin 10% (Grifols)

N/A

Report date: 2026/05/14 20:00:28

Base Information

Drug NameImmune globulin 10% (Grifols)
Drug Alias NameIVIG 10% - KedrionKedrion IVIG 10%IGIV (Grifols)Gamunex-IGIVGamunex-C +[13] 
ClassificationBiologics > Blood components
Mechanisms of ActionImmunostimulantsBeta amyloid A4 protein inhibitors
TargetsBeta amyloid A4 protein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Obsessive-Compulsive DisorderAnxiety Disorders +[25] 
Global Approved IndicationsImmunologic Deficiency SyndromesPurpura, Thrombocytopenic, IdiopathicPolyradiculoneuropathy, Chronic Inflammatory Demyelinating
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2003/08/27
Country/TerritoryCzechiaBelgiumCanada +[10] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesUniversity of Texas Southwestern Medical CenterGrifols Therapeutics LlcAlbert Einstein College Of Medicine Inc +[4] 
Inactive CompaniesUtah State UniversityUniversity Of GiessenUniversity Of Calgary +[6] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)PainImmunologic Deficiency Syndromes +[10] 
Inactive IndicationsObsessive-Compulsive DisorderAnxiety DisordersTibial Fractures +[15] 

Other Information

ATC CodeJ06BA01
Related LinksN/A